DEPLIPIDO Study: Functional and Lipidomic Analysis of Plasma HDL in Patients With Depression Compared to Controls
NCT ID: NCT05099341
Last Updated: 2025-09-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
90 participants
INTERVENTIONAL
2021-10-01
2027-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
It is therefore important to better understand the mechanisms linking depression and cardiovascular disease.
Among the hypotheses that may account for the increased cardiovascular risk in patients with depression, lipid abnormalities are likely to play a crucial role.
Thus, qualitative and functional abnormalities in HDL lipoproteins are an important line of research, insofar as these lipid abnormalities have been recognized as important atherogenic abnormalities in populations at high cardiovascular risk, which is the case of patients with depression.
In this clinical, epidemiological and scientific context, a collaborative study undertaken by both the Department of Psychiatry of the Dijon Bourgogne University Hospital of and the INSERM LNC-UMR 1231 (PADYS) Laboratory of the UNIVERSITY OF BOURGOGNE FRANCHE-COMTE is an original translational research project, and the first study to perform a lipidomic analysis of HDL, coupled with a functional analysis of these lipoproteins in depression.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Blood Biomarkers in Major Depression
NCT02209142
PROSPECTIVE EVALUATION OF BLOOD BIOMARKERS AS AN AID TO DIAGNOSTIC AND TREATMENT IN DRUG-NAIVE PATIENTS WITH DEPRESSION
NCT06369792
Associations Between Depression and Cardiovascular Disease - a Study of Patients With Late Onset Depression
NCT00818506
Inflammatory Markers and Resistant Depression
NCT02847533
Incidence of Depression and Its Complications After Surgical Site Infection - ISODEP.
NCT07125196
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with recurrent depression with a number of depressive episodes ≥ 3
HDRS-17 depression scale
Measuring the severity of depression
Blood sampling
3 tubes of 5 ml
Patients with a first depressive episode
HDRS-17 depression scale
Measuring the severity of depression
Blood sampling
3 tubes of 5 ml
Healthy, non-depressed subjects
HDRS-17 depression scale
Measuring the severity of depression
Blood sampling
3 tubes of 5 ml
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HDRS-17 depression scale
Measuring the severity of depression
Blood sampling
3 tubes of 5 ml
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient who has provided oral consent
* Adult with moderate to severe depression according to DSM-5 criteria (Hamilton HDRS-17 score ≥ 18), with a number of depressive episodes ≥ 3
* PATIENTS PRESENTING WITH A FIRST DEPRESSIVE EPISODE
* Patient who has provided oral consent
* Adult with moderate to severe characterized depression according to DSM-5 criteria (Hamilton HDRS-17 scale score ≥ 18) presenting with a first depressive episode.
* CONTROLS
* Person who has provided oral consent
* Adult who has never shown signs of depression
Exclusion Criteria
* Person subject to a measure of legal protection (curatorship, guardianship)
* Pregnant or breastfeeding women
* Adult unable to express consent
* Minors
* Person with a metabolic syndrome (according to NCEP/ATP-III criteria: 3 of the following 5 criteria: Waist circumference ≥ 102 cm in males and ≥ 88cm in females, Triglycerides \> 1.50 g/L, HDL-Cholesterol \< 0.40 g/L in H, HDL-Cholesterol \< 0.50 g/L in F, Blood pressure ≥130/85mmHg, Fasting blood glucose ≥ 1.10 g/L),
* Person with type 1 or type 2 diabetes,
* Person with a mild depressive episode (HDRS-17\<18),
* Person with concomitant antipsychotic treatment
* Person with bipolar disorder,
* Person with a moderate to severe alcohol use disorder according to DSM-5 criteria
* Person with schizophrenia,
* Person with a persistent delusional disorder,
* Person with an autism spectrum disorder.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire Dijon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chu Dijon Bourgogne
Dijon, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHAUVET CRBFC-E 2019
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.